Abcam, ab320087, Anti-SGLT2 antibody [EPR29167-46] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal SGLT2 antibody. Carrier free. Suitable for IHC-P, mIHC and reacts with Transfected cell line - Human, Human samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR29167-46,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:IHC-P, mIHCSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.,
Specificity:The immunogen shares no sequence similarity with SLC5A1. Based on the immunogen sequence, we do not expect this antibody to cross-react with SLC5A1. No cross-reactivity testing has been performed.

Product details:
ab320087 is the carrier-free version of
ab320086
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
SGLT2 also known as sodium-glucose co-transporter 2 is a protein responsible for reabsorbing glucose in the renal proximal convoluted tubule. It carries glucose along with sodium ions across cell membranes enabling glucose reabsorption from the glomerular filtrate back into the bloodstream a process essential for the maintenance of glucose homeostasis. This protein has a molecular weight of approximately 75 kDa. SGLT2 is mostly expressed in the renal epithelial cells located within the kidney's proximal tubule.
Biological function summary
Sodium-glucose co-transporter 2 plays a central role in renal glucose reabsorption. It operates as part of a vital mechanism in the kidney where it engages in the active transport of glucose against its concentration gradient facilitated by the sodium gradient produced by the Na⁺/K⁺-ATPase pump. This transporter ensures minimal loss of glucose in urine maintaining energy balance and blood glucose levels.
Pathways
SGLT2 is involved in glucose and sodium transport pathways critical for glycolytic and gluconeogenic processes. These pathways are key for energy production and glucose homeostasis. It works closely with proteins like GLUT2 which operates in the basolateral membrane of renal tubular cells to further transfer reabsorbed glucose into the bloodstream. Together these proteins form a tightly regulated network that maintains normal blood glucose levels.
SGLT2 has a significant impact on diabetes and cardiovascular disease. Inhibitors of SGLT2 are effective treatments for type 2 diabetes by preventing glucose reabsorption leading to increased glucose excretion through urine and improved glycemic control. The glucose-lowering effect also contributes to reducing risks associated with cardiovascular diseases. In this context SGLT2 interacts with protein targets like insulin where its modulation offers therapeutic efficacy in managing hyperglycemia.